

Zydus receives USFDA nod for diabetes drug

11 September 2018 | News

The company has received the tentative approval from the USFDA for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg indicated for treating diabetes, in the American market.



Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

The company has received the tentative approval from the USFDA for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg indicated for treating diabetes, in the American market.

It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally).

Sitagliptin is in a class of medications called dipeptidyl peptidase—4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high.

The group has more than 217 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs).